Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients, JCO, vol.32, issue.15, pp.1620-1629, 2014. ,
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib, Clin Genitourin Cancer, vol.11, issue.2, pp.107-114, 2013. ,
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis, J Clin Pharmacol, vol.53, issue.5, pp.491-504, 2013. ,
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey, Eur J Cancer, vol.50, issue.12, pp.2050-2056, 2014. ,
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis, Cancer Chemother Pharmacol, vol.66, issue.2, pp.357-371, 2010. ,
Phase I trial of pazopanib in patients with advanced cancer, Clin Cancer Res, vol.15, issue.12, pp.4220-4227, 2009. ,
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, JCO, vol.28, issue.14, pp.2381-2388, 2010. ,
How to report toxicity associated with targeted therapies?, Ann Oncol, vol.27, issue.8, pp.1633-1638, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01987742
Safety data from randomized controlled trials: applying models for recurrent events, Pharmaceut Statist, vol.15, issue.4, pp.315-323, 2016. ,
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254, Lancet Oncol, vol.17, issue.5, pp.663-670, 2016. ,
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members, Ann Oncol, vol.27, issue.1, pp.192-198, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01812694
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, vol.17, issue.12, pp.1732-1742, 2016. ,
Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care, Oncologist, vol.19, issue.6, pp.669-680, 2014. ,
A qualifier Q for the survival function to describe the prevalence of a transient condition, Stat Med, vol.10, issue.3, pp.413-421, 1991. ,
Non-parametric methods for analysing recurrent complications of varying severity, Stat Med, vol.14, issue.24, pp.2701-2712, 1995. ,
When are "positive" clinical trials in oncology truly positive?, J Natl Cancer Inst, vol.103, issue.1, pp.16-20, 2011. ,
ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, vol.28, issue.10, pp.2340-2366, 2017. ,
Adherence to therapy with oral antineoplastic agents, J Natl Cancer Inst, vol.94, issue.9, pp.652-661, 2002. ,
Treatment satisfaction and adherence to oral chemotherapy in patients with cancer, J Oncol Pract, vol.13, issue.5, pp.474-485, 2017. ,
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors, JCO, vol.27, pp.3141-3147, 2009. ,
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, vol.9, issue.1, pp.327-337, 2003. ,
Evidence for therapeutic drug monitoring of targeted anticancer therapies, J Clin Oncol, vol.30, issue.32, pp.4017-4025, 2012. ,